XML 136 R21.htm IDEA: XBRL DOCUMENT
v3.25.1

Sales of Products | 12 Months Ended
--- | ---
Dec. 31, 2024
Sales of Products |
Sales of Products | 13. Sales of Products The Company’s products consist of both gold flotation concentrates which in 2024 and 2023 were sold to a broker, H&H Metals Corp. (“H&H”), and an unrefined gold-silver product known as doré which is sold to a precious metal refinery. Revenue is recognized upon the completion of the performance obligations and transfer of control of the product to the customer, and the transaction price can be determined or reasonably estimated. For gold flotation concentrate sales, the performance obligation is met when the transaction price can be reasonably estimated, and revenue is recognized generally at the time when risk is transferred to H&H based on contractual terms. Based on contractual terms, the Company has determined the performance obligation is met and title is transferred to H&H when the Company receives its first provisional payment on the concentrate because, at that time, 1) legal title is transferred to the customer, 2) the customer has accepted the concentrate lot and obtained the ability to realize all of the benefits from the product, 3) the concentrate content specifications are known, have been communicated to H&H, and H&H has the significant risks and rewards of ownership to it, 4) it is very unlikely a concentrate will be rejected by H&H upon physical receipt, and 5) the Company has the right to payment for the concentrate. Concentrates lots that have been sold are held at the New Jersey Mill for up to 60 days, until H&H provides shipping instructions. The Company’s concentrate sales sometimes involve variable consideration, as they can be subject to changes in metals prices between the time of shipment and their final settlement. However, the Company can reasonably estimate the transaction price for the concentrate sales at the time of shipment using forward prices for the estimated month of settlement, and previously recorded sales and accounts receivable are adjusted to estimated settlement metals prices until final settlement for financial reporting purposes. The embedded derivative contained in concentrate sales is adjusted to fair value through earnings each period prior to final settlement. It is unlikely a significant reversal of revenue for any one concentrate lot will occur. As such, the Company uses the expected value method to price the concentrate until the final settlement date occurs, at which time the final transaction price is known. At December 31, 2024, metals that had been sold but not final settled included 6,466 ounces of gold of which 1,283 ounces were sold at a predetermined price with the remaining 5,183 ounces exposed to future price changes until prices are locked in based on the month of settlement. The Company has received provisional payments on the sale of these ounces with the remaining amount due reflected in gold sales receivable. Sales and accounts receivable for concentrate shipments are recorded net of charges for treatment and other charges negotiated by us with H&H, which represent components of the transaction price. Charges are estimated by the Company upon transfer of risk of the concentrates based on contractual terms, and actual charges typically do not vary materially from estimates. Costs charged by the customer include fixed treatment, refining and costs per ton of concentrate and may include penalty charges for lead and zinc content above a negotiated baseline as well as excessive moisture. For sales of doré and of metals from doré, the performance obligation is met, the transaction price is known, and revenue is recognized at the time of transfer of control of the agreed-upon metal quantities to the customer. Sales of products by metal for the years ended December 31, 2024 and 2023 were as follows:
|  | 2024 |  |  | 2023 |
Gold |  | $ | 26,406,937 |  |  | $ | 14,308,098 |
Silver |  |  | 121,882 |  |  |  | 55,747 |
Less: Smelter and refining charges |  |  | (763,446 | ) |  |  | (707,112 | )
Total |  | $ | 25,765,373 |  |  | $ | 13,656,733 |
Sales by significant product type for the years ended December 31, 2024 and 2023 were as follows:
|  | 2024 |  |  | 2023 |
Concentrate sales to H&H |  | $ | 25,492,380 |  |  | $ | 13,518,628 |
Doré sales to refineries |  |  | 272,993 |  |  |  | 138,105 |
Total |  | $ | 25,765,373 |  |  | $ | 13,656,733 |
In 2024 and 2023, flotation concentrates sold to H&H accounted for 99% of all gold sales. The remaining 1% was doré sold to a third party. At December 31, 2024 and 2023, the Company’s gold sales receivable balance related to contracts with customers of $1,578,694 and $1,038,867, respectively, consist only of amounts due from H&H. There is no allowance for doubtful accounts. The Company has determined its contracts do not include a significant financing component. For doré sales, payment is received at the time the performance obligation is satisfied. Consideration for concentrate sales is variable, and payment is received for a significant portion of the estimated value of concentrate parcels at the time the performance obligation is satisfied.

X
- References No definition available. + Details
Name: | njmc_SalesOfProductsAbstract
Namespace Prefix: | njmc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | njmc_SalesOfProductsDisclosureTextBlock
Namespace Prefix: | njmc_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration